+++Too bad there is not a “poison” pill in effect.
I agree CL, this BOD would sell out for right price IMO, not that it matters, we'll make money as they will, just not as much....
I don't think the PPS today is related to Monto's chat, something else is up.
My guess is FDA protocol negotiations for HEP C Phase Ib studies are close to finalization and the potential for an HIV Phase I study is on the table right now. Preston Marx/Stephen Smith should have some primate data to report, they will publish of course, but PPHM could release some data....
DUKE'S expertise as you well know lies in designing trials to test investigational compounds to treat ---treatment experienced patients for HIV and then there is the HCV specialist there, John McHutchinson, who may conduct/potentially be one of the PI's for Rib + Tarv planned Phase Ib study. DUKE was one of the founding members of the ACTIS organization. Bodes very well for Tarvacin if DUKE wants to test the mab. The last time I spoke to PPHM management, I was advised an HCV specialist at DUKE was following/monitoring the Godofsky study....I did a little research!
PPHM has assembled a top notch SRB, now they need to attract physicians....top notch ones too...
katie...
News 
Market Data 
Discover 
AI
